SymBio Pharmaceuticals - Treakisym has positive DLBCL results
On 5 November 2019, SymBio announced it obtained positive results in its pivotal Phase III clinical trial of Treakisym (bendamustine) in patients...
1.7k Views
SymBio Pharmaceuticals - Preparing to establish own sales organisation
SymBio announced in October that it has begun preparations to establish its own sales organisation to market Treakisym and other anticancer drugs...
124 Views
SymBio Pharmaceuticals - Self-commercialization gains favor
With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to...
165 Views
SymBio Pharmaceuticals - Self-commercialisation gains favour
With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to...
108 Views
SymBio Pharmaceuticals - Licence agreement for IONSYS terminated
The licence agreement between SymBio and The Medicines Company (MDCO) for the exclusive rights to develop the IONSYS (SyB P-1501) pain patch in...
153 Views